Avidity Biosciences, Inc. (RNA)

SAN DIEGO , Oct. 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced that it will deliver late-breaking oral and poster presentations at the 30th Annual International Congress of the World Muscle Society (WMS), to be held October 7-11, 2025, in Vienna, Austria. The data to be presented at WMS will reinforce and build on the positive data announced by Avidity in September 2025 which showed reversal of disease progression and unprecedented improvement compared to baseline and natural history across multiple functional measures for participants living with Duchenne muscular dystrophy mutations amenable to exon 44 skipping (DMD44) treated continuously with delpacibart zotadirsen (del-zota) for one year in the Phase 1/2 EXPLORE44® and Phase 2 EXPLORE44-OLE™ trials.

SAN DIEGO , Sept. 15, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it has closed its previously announced underwritten public offering of 17,250,000 shares of its common stock, including 2,250,000 shares sold pursuant to the underwriters' full exercise of their option to purchase additional shares, at a price to the public of $40.00 per share.

U.S. stock futures were higher this morning, with the Dow futures gaining around 0.2% on Thursday.

Avidity Biosciences, Inc. (NASDAQ:RNA ) Discusses on Redefining the Treatment of Duchenne Muscular Dystrophy Conference Call September 10, 2025 8:00 AM EDT Company Participants Katja Lange - Senior VP & Chief Business Officer Sarah Boyce - President, CEO & Director Steven Hughes - Chief Medical Officer W. Flanagan - Chief Scientific Officer Presentation Katja Lange Senior VP & Chief Business Officer Good morning, and thank you so much for joining us today.

SAN DIEGO , Sept. 10, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that it intends to offer and sell, subject to market and other conditions, $500.0 million of shares of its common stock in an underwritten public offering.

-- Unprecedented improvement compared to baseline and natural history in multiple functional measures including Time to Rise from Floor (TTR), 4-Stair Climb (4SC), Performance of Upper Limb (PUL) and 10-Meter Walk/Run Test (10mWRT) at approximately one year -- -- Unprecedented rapid reduction in creatine kinase (CK) to near normal levels maintained over 16 months of follow-up and 25% increase of normal in dystrophin production, reflecting sustained muscle fiber protection -- -- Avidity remains on track to submit Biologics License Application (BLA) at year end 2025 for accelerated approval -- -- Investor and analyst webcast event today at 8:00 a.m. ET -- SAN DIEGO , Sept.

Avidity Biosciences, Inc. (NASDAQ:RNA ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 1:50 PM EDT Company Participants Kathleen Gallagher - Chief Program Officer Michael MacLean - Chief Financial Officer Katja Lange - Senior VP & Chief Business Officer Presentation Unknown Analyst Good afternoon. Thank you for coming to the Morgan Stanley Healthcare Conference.

Avidity Biosciences, Inc. (NASDAQ:RNA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 12:45 PM EDT Company Participants Michael MacLean - Chief Financial Officer Kathleen Gallagher - Chief Program Officer Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Great. Thanks, everyone, for being here.

Avidity Biosciences surges 36% on reports that Novartis may eye a deal, with talks said to be early and interest from other suitors possible.

Avidity (RNA) Q2 Revenue Jumps 88%

Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE™ trial, and initiated global confirmatory Phase 3 study Planned del-zota BLA submission at year end 2025 for DMD44 on track to be Avidity's first BLA submission On track for three potential BLA submissions over a 12-month period Strong balance sheet and cash runway to mid-2027 enabling global commercial launch readiness; first potential commercial launch in U.S. in 2026  SAN DIEGO , Aug. 7, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported financial results for the second quarter ended June 30, 2025 and highlighted recent progress. "Avidity continues to deliver on its leadership in RNA therapeutics as we prepare for three potential BLA submissions in a 12-month period with strong clinical data, regulatory progress, and operational execution," said Sarah Boyce, president and chief executive officer of Avidity.

Avidity Biosciences stock rocketed Wednesday on a report Novartis made an attempt to buy the rare disease-focused biotech company.

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times reported, citing people familiar with the matter

-- Topline data readout from HARBOR study anticipated in Q2 2026 -- -- Marketing application submissions for del-desiran including in U.S., EU and Japan anticipated to start in H2 2026; on track to potentially be the first globally approved drug for DM1-- -- On track to share updates from ongoing MARINA-OLE™ trial of del-desiran including long-term 4 mg/kg efficacy and safety data in Q4 2025 -- SAN DIEGO , July 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the completion of enrollment in the ongoing global Phase 3 HARBOR™ clinical trial of delpacibart etedesiran (del-desiran) for people living with myotonic dystrophy type 1 (DM1). Topline data from HARBOR, the first global Phase 3 clinical trial in DM1, are anticipated in the second quarter of 2026.